Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 6/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526844 | 1.00 | MAP2K1 (1.00) | MAP2K1AXLNR4A2CREBBPKDM4E | |
| SCHEMBL28164021 | 0.89 | MAP2K1 (0.81) | MAP2K1AXLNR4A2CREBBPKDM4E | |
| Methoxymethane SCHEMBL28146835 | 0.87 | MAP2K1 (0.77) | MAP2K1AXLCNR2ADORA2AMTNR1A | |
| SCHEMBL27709892 | 0.86 | MAP2K1 (0.76) | MAP2K1AXLNR4A2CREBBPKDM4E | |
| SCHEMBL26047920 | 0.85 | MAP2K1 (0.74) | MAP2K1AXLNR4A2CREBBPCNR2 | |
| SCHEMBL7956049 | 0.85 | MAP2K1 (0.74) | MAP2K1CNR2ADORA2AMTNR1AKMT2A | |
| SCHEMBL1940550 | 0.84 | MAP2K1 (0.73) | MAP2K1AXLCNR2ADORA2AMTNR1A | |
| SCHEMBL2991525 | 0.83 | MAP2K1 (0.71) | MAP2K1AXLCNR2ADORA2AMTNR1A | |
| SCHEMBL985214 | 0.83 | MAP2K1 (0.71) | MAP2K1AXLKDM4ECNR2ADORA2A | |
| SCHEMBL29468201 | 0.83 | MAP2K1 (0.71) | MAP2K1AXLKDM4ECNR2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218546-A | The synthesis technique of 1H-pyrrolo-[2,3-B] pyridine-3-carboxylic acid methyl esters | SHANGHAI TITAN TECHNOLOGY CO LTD | 2016-01-06 | — | — | CN | claimed |
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4380562-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | The Rockefeller University (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| WO-2023015156-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | HUDSPETH A JAMES (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023015156-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | HUDSPETH A JAMES (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1704147-A1 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | Pfizer Italia S.r.l. (IT) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005063747-A1 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | PFIZER ITALIA S.R.L. (IT) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005028475-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | ADH1C, SIK1, PKN2 | MAP2K1 550/4885AXL 3408/4885NR4A2 4880/4885 |
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | LATS1, LATS2, YAP1 | MAP2K1 1158/4885AXL 1402/4885NR4A2 2747/4885 |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | MAP2K1 337/4885AXL 3715/4885NR4A2 3136/4885 |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | TNNI3, TNNT2, TNNC1 | MAP2K1 3889/4885AXL 2869/4885NR4A2 3916/4885 |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | MAP2K1 403/4885AXL 1103/4885NR4A2 4619/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | MAP2K1 3894/4885AXL 442/4885NR4A2 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.